Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01914393
Other study ID # D1050302
Secondary ID 2013-001694-24
Status Completed
Phase Phase 3
First received
Last updated
Start date September 30, 2013
Est. completion date October 17, 2018

Study information

Verified date December 2019
Source Sunovion
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326


Recruitment information / eligibility

Status Completed
Enrollment 702
Est. completion date October 17, 2018
Est. primary completion date October 17, 2018
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria:

- Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' participation in the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) or Independent Ethics Committee (IEC) requirements, the subject will complete an informed assent when developmentally appropriate, to participate in the study before conduct of any study-specific procedures.

- Subject has completed Study D1050301 (Visit 9) OR

- Subject has completed Study D1050325 (Visit 9) OR

- Subject has completed Study D1050326 (Visit 8)

- Subject is judged by the investigator to be appropriate for participation in a 104-week clinical trial in an outpatient setting involving open-label lurasidone treatment, and is able to comply with the protocol.

- A reliable informant (eg, parent, legal guardian, or caregiver) must be available to accompany the subject at each visit. For subjects entering from Study D1050325, the reliable caregiver must also oversee the administration of the study drug throughout the study

- Females who participate in this study:

- are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-

- practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken; -OR-

- are sexually active and willing to use a medically effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.

- Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.

Exclusion Criteria:

- Subject is considered by the investigator to be at imminent risk of suicide.

- Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed

Locations

Country Name City State
Bulgaria MHC - Ruse, EOOD Ruse
Bulgaria UMHAT "Alexandrovska" EAD Sofia
Bulgaria MHAT-Targovishte, AD Targovishte
Bulgaria DCC "Mladost M" - Varna, OOD Varna
Colombia Centro de Investigaciones y Proyectos en Neurociencias CIPNA Barranquilla
Colombia E.S.E. Hospital Mental de Antioquia Bello
Colombia Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda Bogota
France CHU Nantes - Hôpital Mère-Enfant Nantes Cedex 1
Hungary Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert Budapest
Hungary Bekes Megyei Pandy Kalman Korhaz Gyula
Korea, Republic of Chonnam National University Hospital Gwangju
Korea, Republic of Inha University Hospital Incheon
Korea, Republic of Chonbuk National University Hospital Jeonju
Korea, Republic of Seoul National University Hospital Seoul Gyeonggi-do
Malaysia University Malaya Medical Centre Kuala Lumpur
Mexico Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C. Culiacan Sinaloa
Mexico Dr. Jessica Rosas Escobar Durango
Mexico Instituto de Investigaciones Aplicadas a la Neurociencia A.C. Durango
Mexico Accelerium S. de R.L. de C.V. Monterrey
Mexico Instituto de Informacion de Investigacion en Salud Mental Monterrey
Mexico Av Modesto Arreola #917 Ote. Col Centro Nuevo León
Philippines Alexian Brothers Health and Wellness Center Davao City
Philippines West Visayas State University Medical Center Iloilo
Philippines National Center for Mental Health Mandaluyong City
Philippines Veterans Memorial Medical Center Quezon City
Poland NZOZ Poradnia Zdrowia Psychicznego Kobierzyce
Poland Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Kliniczmy VI Psychiatrii Mlodziezy Torun
Puerto Rico Centro de Investigacion Clinica Psiquiatrica Caguas
Romania Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia Bucuresti
Romania Spitalul Clinic de Psihiatrie Socola Iasi
Romania Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu" Timisoara Timisoara
Russian Federation Sverdiovsk Regional Clinical Psychiatric Hospital Ekaterinburg
Russian Federation GUZ Lipetsk Regional psychoneurological Hospital #1 Lipetsk
Russian Federation Closed corporation "Scientific Center of Personalized Psychiatry" Moscow
Russian Federation Scientific Center of Personalized Psychiatry Moscow
Russian Federation State Healthcare Institution of Nizhniy Novgordo region "Clinical Psychiatric Hospital #1 of City of Nizhniy Novgorod" Nizhny Novgorod
Russian Federation Bekhterev Institute Saint Petersburg
Russian Federation Center of Recovery Treatment "Pediatric Psychiatry" named after S.S. Mnukhin Saint Petersburg
Russian Federation SHI "City Psychoneurological dispensary #7 (with Hospital)" Saint Petersburg
Russian Federation Regional Clinical Mental Hospital of Saint Sofiya Saratow
Russian Federation FSBSI "Scientific Research Institute of Mental Health" Tomsk
Russian Federation State Healthcare Institution of Yaroslavl Rgion "Yaroslavl Regional clinical Mental Hospital" Yaroslavl
Spain Hospital Marítimo de Torremolinos Torremolinos Málaga
Ukraine RPsH #3 ?hildren Dept SHEI Ivano-Frankivsk SMU Ivano Frankivsk
Ukraine SI Institute of Children and Adolescents Healthcare of NAMSU Kharkiv
Ukraine SI Institute of Neurology, Psychiatry and Narcology of NAMSU Kharkiv
Ukraine TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions Kyiv
Ukraine CI Lviv Regional Clinical Psychiatric Hospital Lviv
Ukraine Odesa Regional Psychoneurological Dispensary, Outpatient Dept. Odesa
Ukraine O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy Poltava
Ukraine CI Kherson Regional Psychiatric Hospital of Kherson RC Stepanivka
Ukraine Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU Ternopil
Ukraine Reg. Psych. Hosp.n.a. O.Yuschenko, Dept. #121 VNMI Vinnitsia
United States Atlanta Center for Medical Research Atlanta Georgia
United States Kennedy Krieger Institute Baltimore Maryland
United States Neurobehavioral medicine Group, LLC Bloomfield Hills Michigan
United States University of Virginia Charlottesville Virginia
United States University of Cincinnati Medical Center Cincinnati Ohio
United States University Hospitals Case Medical Center Cleveland Ohio
United States Ericksen Research & Development, LLC Clinton Utah
United States The Ohio State University Nisonger Center Columbus Ohio
United States Pillar Clinical Research, LLC Dallas Texas
United States Harmonex Neuroscience Research Dothan Alabama
United States Diligent Clinical Trials, Inc Downey California
United States Sarkis Clinical Trials - Parent Gainesville Florida
United States North Shore/Long Island Jewish PRIME Glen Oaks New York
United States Neuroscience, Inc. Herndon Virginia
United States Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340 Lake Charles Louisiana
United States University Of Kentucky Lexington Kentucky
United States Dr. Jeanette Cueva Mount Kisco New York
United States Jersey Shore University Medical Center Neptune New Jersey
United States Montefiore Medical Center PRIME New York New York
United States Cutting Edge Research Group Oklahoma City Oklahoma
United States APG Research, LLC Orlando Florida
United States Clinical Neuroscience Solutions, Inc. Orlando Florida
United States Psychiatric Associates Overland Park Kansas
United States Clinical Research Partners, LLC Petersburg Virginia
United States Carilion Clinic Roanoke Virginia
United States Finger Lakes Clinical Research Rochester New York
United States St. Charles Psychiatric Associates Saint Charles Missouri
United States University of South Florida Saint Petersburg Florida
United States University of California San Francisco Medical Center San Francisco California
United States Medical Research Group of Central Florida Sanford Florida
United States Neuropsychiatric Research Center of Orange County Santa Ana California
United States Attalla Consultants, LLC Smyrna Georgia
United States Richmond Behavioral Associates Staten Island New York
United States University of South Florida Rothman Center of Neuropychiatry Tampa Florida
United States Family Psychiatry of The Woodlands, P.A. The Woodlands Texas

Sponsors (1)

Lead Sponsor Collaborator
Sunovion

Countries where clinical trial is conducted

United States,  Bulgaria,  Colombia,  France,  Hungary,  Korea, Republic of,  Malaysia,  Mexico,  Philippines,  Poland,  Puerto Rico,  Romania,  Russian Federation,  Spain,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs) The Safety population consists of all subjects who received at least one dose of study drug in this study. During 104 Weeks (2-years) treatment period
Secondary Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score Change from Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score for subjects continued from study D1050301.
PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210 Higher values of PANSS total score represents greater severity of illness.
Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in PANSS Positive Subscale Score Change from Baseline in PANSS Positive Subscale Score for subjects continued from study D1050301 The Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness /persecution, and hostility; Positive subscale (range 7-49) is calculated as sum of Items P1 to P7 in the positive subscale Higher values of PANSS sub-scale scores represent greater severity Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in PANSS Negative Subscale Score Change from Baseline in PANSS Negative Subscale Score for subjects continued from study D1050301 The Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; Negative subscale (range 7-49) is calculated as sum of Items N1 to N7 in the negative subscale Higher values of PANSS sub-scale scores represent greater severity of illness. Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in PANSS General Psychopathology Subscale Score Change from Baseline in PANSS General Psychopathology Subscale Score for subjects continued from study D1050301 The General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation; General psychopathology subscale (range 16-112) is calculated as sum of Items G1 to G16 in the general psychopathology subscale Higher values of PANSS sub-scale scores represent greater severity of illness. Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in PANSS Excitability Subscale Score Change from Baseline in PANSS Excitability Subscale Score for subjects continued from study D1050301 Subscale of Excitability consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control. The sum of the four items ranges from 4 to 28 Higher values of PANSS sub-scale scores represent greater severity of illness. Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in the Clinical Global Impression -Severity Score Change from Baseline in the Clinical Global Impression -Severity Score for subjects continued from study D1050301 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score Change from Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score for subjects continued from study D1050301 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050301
The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows:
% Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.
Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score Change from Baseline in ABC Irritability Subscale Score for subjects continued from study D1050325 The Aberrant Behavior Checklist (ABC) contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).
Irritability Subscale Score is calculated as summing of items 2, 4, 8, 10, 14, 19, 25, 29, 34, 36, 41, 47, 50, 52, and 57; as a result, ABC irritability subscale score ranges from 0 to 45.
In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score Change from Baseline in ABC Lethargy and Social Withdrawal Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).
Lethargy and Social Withdrawal Subscale Score is calculated as summing of items 3, 5, 12, 16, 20, 23, 26, 30, 32, 37, 40, 42, 43, 53, 55, and 58. ABC Lethargy and Social Withdrawal Subscale Score ranges from 0 to 48.
In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score Change from Baseline in ABC Stereotypic Behavior Subscale Score for subjects continued from study D1050325. The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Stereotypic behavior Subscale Score is calculated as summing of 6, 11, 17, 27, 35, 45, and 49 items . ABC Stereotypic behavior Subscale Score ranges from 0 to 21. Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). To score the ABC, the individual items for each subscale are simply summed to their respective totals. It is inappropriate to compute a "total aberrant score", based on a summation of all 58 items, as the subscales are largely independent. In general, higher values of ABC subscale scores represent greater severity Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score Change from Baseline in ABC Hyperactivity and Noncompliance Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).
Hyperactivity and noncompliance Subscale Score is calculated as summing of 1, 7, 13, 15, 18, 21, 24, 28, 31, 38, 39, 44, 48, 51, 54, and 56 items. ABC hyperactivity and noncompliance Subscale Score ranges from 0 to 48.
In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score Change from Baseline in ABC Inappropriate Speech Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).
Inappropriate speech Subscale Score is calculated as summing of 9, 22, 33, and 46 items. ABC inappropriate speech Subscale Score ranges from 0 to 12.
In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Clinical Global Impression (CGI) - Severity Score Change from Baseline in Clinical Global Impression (CGI) - Severity Score for subjects continued from study D1050325 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS) Change from Baseline in CY-BOCS for subjects continued from study D1050325 CY-BOCS used in the study is a modification of the Yale-Brown Obsessive Compulsive Scale and contains total 7 items for compulsion. "Obsessions" section was removed as it is difficult to obtain valid information given typical language/cognitive delays in the population. Each item of the compulsive scale ranges from 0 to 4. At this time, item 1b ("compulsion-free interval") and item 6 ("peculiarity of the behavior") are not being used in the scoring. Item 7 is a rating for reliability, ranging from 0 (excellent) to 3 (poor). It reflects the interview's judgment regarding the confidence in the data collected hence it is not counted in the CY-BOCS total score. The CY-BOCS compulsion total score is the sums of item 1-5. As a result, the CY-BOCS compulsion total score may range from 0 to 20. In general, higher values of CY-BOCS scores represent greater severity of illness Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score Change from Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score for subjects continued from study D1050325 The CGSQ is comprised of total 21 items. Each item is rated on a 5-point Likert-type scale (1 (not at all a problem) to 5 (very much a problem)) and is grouped into three subscales: objective strain, subjective externalized strain, and subjective internalized strain. The 3 subscale scores are calculated as the averages of the corresponding individual items, which range in severity from 1 to 5.
Higher scores on each of these subscale scales indicate greater strain. A global strain score is calculated by summing the three subscales (i.e., objective strain, subjective externalized strain, and subjective internalized strain) to provide an indication of the total impact of the special demands on the family. Global strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain
Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score Change from Baseline in CDRS-R Total Score for subjects continued from study D1050326 CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with depression in childhood. The CDRS-R is administered separately to the patient and to the caregiver; among 17 items, 14 items are based on separate interviews with child and parent, 3 items are based solely on the rater's observation of child (ie, no questions).The 14 items are rated on a 1 (no psychopathology) to 7 (most psychopathology) scale, where a rating of 3 represents mild psychopathology. The 3 items (sleep disturbance, appetite disturbance, listless speech) are rated on a 1 (no pathology) to 5 (most pathology) scale. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score Change from Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score for subjects continued from study D1050326 The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity. Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score Change from Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score for subjects continued from study D1050326 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050326
The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows:
% Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.
Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score Change from Baseline in PAR Total Score for subjects continued from study D1050326 The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6 17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. Scores of 8 or 9 are not counted in the summation as per the PARS instructions. The PARS total score over all 7 questions ranges in value from 0 to 35.A higher PARS total score Open-Label Baseline, Week 28, Week 52, and Week 104
Secondary Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score Change from Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score for subjects continued from study D1050326 The ADHD-RS IV is a validated scale that measures the behaviors of children with ADHD. The ADHD-RS IV consists of 18 items reflecting current symptomatology of ADHD based on DSM-IV-TR criteria. Each item is scored from a range of 0 (no symptoms) to 3 (severe symptoms) with total scores ranging from 0 to 54. The 18 items may be grouped into two sub-scales: hyperactivity/impulsivity (even number items 2 through 18) and inattentiveness (odd number items 1 through 17), ranging from 0 to 27. A higher ADHD-RS total score and sub-scales scores are associated with greater illness severity Open-Label Baseline, Week 28, Week 52, and Week 104
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1